| First Author | Sawmiller D | Year | 2023 |
| Journal | J Biol Chem | Volume | 299 |
| Issue | 7 | Pages | 104846 |
| PubMed ID | 37211092 | Mgi Jnum | J:337947 |
| Mgi Id | MGI:7508391 | Doi | 10.1016/j.jbc.2023.104846 |
| Citation | Sawmiller D, et al. (2023) Targeting apolipoprotein E and N-terminal amyloid beta-protein precursor interaction improves cognition and reduces amyloid pathology in Alzheimer's mice. J Biol Chem 299(7):104846 |
| abstractText | Apolipoprotein E (apoE) interaction with amyloid beta-protein precursor (APP) has garnered attention as the therapeutic target for Alzheimer's disease (AD). Having discovered the apoE antagonist (6KApoEp) that blocks apoE binding to N-terminal APP, we tested the therapeutic potential of 6KApoEp on AD-relevant phenotypes in amyloid beta-protein precursor/presenilin 1 (APP/PS1) mice that express each human apoE isoform of apoE2, apoE3, or apoE4 (designated APP/PS1/E2, APP/PS1/E3, or APP/PS1/E4 mice). At 12 months of age, we intraperitoneally administered 6KApoEp (250 mug/kg) or vehicle once daily for 3 months. At 15 months of age, blockage of apoE and N-terminal APP interaction by 6KApoEp treatment improved cognitive impairment in most tests of learning and memory, including novel object recognition and maze tasks in APP/PS1/E2, APP/PS1/E3, and APP/PS1/E4 mice versus each vehicle-treated mouse line and did not alter behavior in nontransgenic littermates. Moreover, 6KApoEp therapy ameliorated brain parenchymal and cerebral vascular beta-amyloid deposits and decreased abundance of amyloid beta-protein (Abeta) in APP/PS1/E2, APP/PS1/E3, and APP/PS1/E4 mice versus each vehicle-treated mouse group. Notably, the highest effect in Abeta-lowering by 6KApoEp treatment was observed in APP/PS1/E4 mice versus APP/PS1/E2 or APP/PS1/E3 mice. These effects occured through shifting toward lessened amyloidogenic APP processing due to decreasing APP abundance at the plasma membrane, reducing APP transcription, and inhibiting p44/42 mitogen-activated protein kinase phosphorylation. Our findings provide the preclinical evidence that 6KApoEp therapy aimed at targeting apoE and N-terminal APP interaction is a promising strategy and may be suitable for patients with AD carrying the apoE4 isoform. |
